View
1
Download
0
Category
Preview:
Citation preview
17JADA Middle East vol 2 No 4 Jul-Aug 2011
Recognizing the importance of providing profound anes-thesia for patients under-going invasive dental pro-
cedures, clinicians continually seekto identify an anesthetic solutionthat provides the highest successrate at an affordable cost. Dentistsin the United States have a varietyof anesthetic solutions at their dis-posal (Table 1). Although these solu-tions are considered to be generallyeffective in providing patients witha pain-free oral environment fordental treatment, local anestheticfailure remains a common problemin certain instances. Clinicians con-stantly have sought an anestheticsolution with a better success ratethan that of available anesthetics,which has been demonstrated to bewell below 100 percent, particularlyin procedures affecting the posteriormandible.1-4
Although for some time anestheticsolutions containing lidocaine havebeen used more widely in the UnitedStates than have solutions con-taining other anesthetics, the U.S.Food and Drug Administration’sapproval of articaine for local anes-
Dr. Brandt was a graduate student, Department of Cariology, Restorative Sciences and Endodontics, School of Dentistry, University of Michigan, Ann Arbor,when this article was written. He now is a private practitioner in Jackson, Mich.Ms. Anderson is an emerging technologies librarian, Taubman Health Sciences Libraries, University Library, University of Michigan, Ann Arbor.Dr. McDonald is a clinical professor of dentistry, Department of Cariology, Restorative Sciences and Endodontics, School of Dentistry, University of Michigan,Ann Arbor.Dr. Sohn is an associate professor of dentistry, Department of Cariology, Restorative Sciences and Endodontics, School of Dentistry, University of Michigan,Ann Arbor.Dr. Peters is a professor of dentistry, Department of Cariology, Restorative Sciences and Endodontics, School of Dentistry, University of Michigan, Room 2345,1011 N. University, Ann Arbor, Mich. 48109, e-mail “mcpete@umich.edu”. Address reprint requests to Dr. Peters.
The pulpal anesthetic efficacy of articaineversus lidocaine in dentistryA meta-analysis
Ryan G. Brandt, DDS, MS; Patricia F. Anderson, MLIS; Neville J. McDonald, BDS, MS; Woosung Sohn, DDS, PhD, DrPH; Mathilde C. Peters, DMD, PhD
AB ST RACTBackground. The authors evaluated pub-lished evidence from controlled clinical trialsregarding the efficacy of two local anesthetic solu-tions in providing successful pulpal anesthesia. Methods. The authors searched MEDLINE andEmbase databases to identify peer-reviewed random-ized controlled trials in which researchers directly compared arti-caine and lidocaine local anesthetic solutions in adult partici-pants. They extracted study characteristics and outcomes data asa basis for meta-analysis. They completed subgroup analyses forboth infiltration and mandibular inferior alveolar block anes-thetic techniques.Results. Articaine solutions had a probability of achieving anes-thetic success superior to that of lidocaine, with an odds ratio of2.44 (95 percent confidence interval [CI], 1.59-3.76; P < .0001). Thegreater odds ratio for articaine increased to 3.81 (95 percent CI,2.71-5.36; P < .00001) when the authors analyzed only infiltrationdata. There was weaker, but still significant, evidence of articaine’sbeing superior to lidocaine for mandibular block anesthesia, withan odds ratio of 1.57 (95 percent CI, 1.12-2.21; P = .009), and no dif-ference when the authors considered only symptomatic teeth. Clinical Implications. Research evidence supports using arti-caine versus lidocaine for achieving pulpal anesthesia when theinfiltration mode of administration is used. It is premature to rec-ommend articaine for mandibular block anesthesia in casesinvolving irreversible pulpitis.Key Words. Systematic review; anesthesia; articaine; lidocaine.JADA 2011;142(5):493-504.
JADA 142(5) http://jada.ada.org May 2011 493
S T O R YC O V E R
PETERS.qxp:Layout 1 4/19/11 3:51 PM Page 493
To Add On page 12 add: © 2011 American Dental Association. Republished by Medical Online Publication SAL with permission of American Dental Association. All rights reserved. JADA 2011, Volume 142, No 5, Page 478-479 On page 17 add: © 2011 American Dental Association. Republished by Medical Online Publication SAL with permission of American Dental Association. All rights reserved. JADA 2011, Volume 142, No 5, Page 493-504 On page 31 add: © 2011American Dental Association. Republished by Medical Online Publication SAL with permission of American Dental Association. All rights reserved. JADA 2011, Volume 142, No 5, Page 531-539 On page 40 add: © 2011 American Dental Association. Republished by Medical Online Publication SAL with permission of American Dental Association. All rights reserved. JADA 2011, Volume 142, No 5, Page 506-513 On page 49 add: © 2011 American Dental Association. Republished by Medical Online Publication SAL with permission of American Dental Association. All rights reserved. JADA 2011, Volume 142, No 4, Page 411-414 On page 54 add: © 2011 American Dental Association. Republished by Medical Online Publication SAL with permission of American Dental Association. All rights reserved. JADA 2011, Volume 142, No 4, Page 406-409 On page 59 add: © 2011 American Dental Association. Republished by Medical Online Publication SAL with permission of American Dental Association. All rights reserved. JADA 2011, Volume 142, No 4, Page 441-444 On page 63 add: © 2011 American Dental Association. Republished by Medical Online Publication SAL with permission of American Dental Association. All rights reserved. JADA 2011, Volume 142, No 5, Page 553-555 On page 66 add: © 2011 American Dental Association. Republished by Medical Online Publication SAL with permission of American Dental Association. All rights reserved. JADA 2011, Volume 142, No 5, Page 574 10 JADA Middle East vol 2 No 4 July-August 2011
18 JADA Middle East vol 2 No 4 Jul-Aug 2011494 JADA 142(5) http://jada.ada.org May 2011
thetic use has given clinicians another choice.Lidocaine has been available in the UnitedStates for more than 60 years, whereas articainewas approved for use in the United States in
S T O R YC O V E R
ABBREVIATION KEY. EPT: Electric pulp testing. HCl: Hydrochloride. IAN: Inferior alveolar nerve.RCT: Randomized controlled trial. VAS: Visualanalog scale.
TABLE 1
Available local anesthetic solutions.DURATION OF ACTION
SOLUTION TRADE NAME INFILTRATION(PULPAL)
NERVEBLOCK
(PULPAL)
DURATIONOF EFFECT INSOFT TISSUE
MILLIGRAMSPER
CARTRIDGE
Short Duration,Plain
Lidocainehydrochloride
(HCl) 2percent
Xylocaine (DentsplyPharmaceutical, York, Pa.)
5 minutes Notindicated
2 hours 36
MepivacaineHCl 3 percent
Carbocaine (Eastman Kodak,Rochester, N.Y.), Isocaine(Septodont, New Castle,
Del.), Mepivacaine (Hospira,Lake Forest, Ill.; HenrySchein, Melville, N.Y.),Polocaine (Dentsply
Pharmaceutical), Scandanest(Novocol Pharmaceutical,
Cambridge, Ontario,Canada)
20 to 30minutes
45 to 65minutes
2 to 3 hours 54
Prilocaine HCl4 percent
Citanest Plain (DentsplyPharmaceutical)
10 to 15minutes
45 to 65minutes
3 to 4 hours 72
NormalDuration, WithVasoconstrictor
Articaine HCl4 percent
withepinephrine
1:100,000
Articadent (DentsplyPharmaceutical), Septocaine
(Septodont), Zorcaine(Eastman Kodak)
60 to 75minutes
Up to 120minutes
3 to 5 hours 68
Articaine HCl4 percent
withepinephrine
1:200,000
Articadent (DentsplyPharmaceutical), Septocaine
(Septodont)
60 to 75minutes
Up to 120minutes
3 to 5 hours 68
Lidocaine HCl2 percent
withepinephrine
1:50,000
Lidocaine (CarestreamHealth, Rochester, N.Y.;Hospira; Henry Schein),
Lignospan Forte (NovocolPharmaceutical),
Octocaine 50 (Septodont),Xylocaine (Dentsply)
55 to 65minutes
80 to 90minutes
3 to 5 hours 36
Lidocaine HCl2 percent
withepinephrine
1:100,000
Lidocaine (CarestreamHealth; Hospira; Henry
Schein), Lignospan Standard(Novocol Pharmaceutical),
Octocaine 100 (Septodont),Xylocaine (Dentsply)
55 to 65minutes
80 to 90minutes
3 to 5 hours 36
MepivacaineHCl 2 percent
withlevonordefrin
1:20,000
Carbocaine (EastmanKodak), Isocaine
(Septodont), Mepivacaine(Henry Schein), Polocaine
(Dentsply), Scandanest(Novocol Pharmaceutical)
40 to 60minutes
60 to 90minutes
3 to 5 hours 36
Prilocaine HCl4 percent
withepinephrine
1:200,000
Citanest Forte (Dentsply) 35 to 45minutes
50 to 70minutes
3 to 6 hours 72
Long Duration BupivacaineHCl 0.5
percent withepinephrine
1:200,000
Bupivacaine (Hospira),Marcaine (Carestream
Health), Vivacaine (NovocolPharmaceutical)
Up to 7 hours Up to 7hours
Up to 12 hours 9
PETERS.qxp:Layout 1 4/19/11 3:51 PM Page 494
19JADA Middle East vol 2 No 4 Jul-Aug 2011494 JADA 142(5) http://jada.ada.org May 2011
thetic use has given clinicians another choice.Lidocaine has been available in the UnitedStates for more than 60 years, whereas articainewas approved for use in the United States in
S T O R YC O V E R
ABBREVIATION KEY. EPT: Electric pulp testing. HCl: Hydrochloride. IAN: Inferior alveolar nerve.RCT: Randomized controlled trial. VAS: Visualanalog scale.
TABLE 1
Available local anesthetic solutions.DURATION OF ACTION
SOLUTION TRADE NAME INFILTRATION(PULPAL)
NERVEBLOCK
(PULPAL)
DURATIONOF EFFECT INSOFT TISSUE
MILLIGRAMSPER
CARTRIDGE
Short Duration,Plain
Lidocainehydrochloride
(HCl) 2percent
Xylocaine (DentsplyPharmaceutical, York, Pa.)
5 minutes Notindicated
2 hours 36
MepivacaineHCl 3 percent
Carbocaine (Eastman Kodak,Rochester, N.Y.), Isocaine(Septodont, New Castle,
Del.), Mepivacaine (Hospira,Lake Forest, Ill.; HenrySchein, Melville, N.Y.),Polocaine (Dentsply
Pharmaceutical), Scandanest(Novocol Pharmaceutical,
Cambridge, Ontario,Canada)
20 to 30minutes
45 to 65minutes
2 to 3 hours 54
Prilocaine HCl4 percent
Citanest Plain (DentsplyPharmaceutical)
10 to 15minutes
45 to 65minutes
3 to 4 hours 72
NormalDuration, WithVasoconstrictor
Articaine HCl4 percent
withepinephrine
1:100,000
Articadent (DentsplyPharmaceutical), Septocaine
(Septodont), Zorcaine(Eastman Kodak)
60 to 75minutes
Up to 120minutes
3 to 5 hours 68
Articaine HCl4 percent
withepinephrine
1:200,000
Articadent (DentsplyPharmaceutical), Septocaine
(Septodont)
60 to 75minutes
Up to 120minutes
3 to 5 hours 68
Lidocaine HCl2 percent
withepinephrine
1:50,000
Lidocaine (CarestreamHealth, Rochester, N.Y.;Hospira; Henry Schein),
Lignospan Forte (NovocolPharmaceutical),
Octocaine 50 (Septodont),Xylocaine (Dentsply)
55 to 65minutes
80 to 90minutes
3 to 5 hours 36
Lidocaine HCl2 percent
withepinephrine
1:100,000
Lidocaine (CarestreamHealth; Hospira; Henry
Schein), Lignospan Standard(Novocol Pharmaceutical),
Octocaine 100 (Septodont),Xylocaine (Dentsply)
55 to 65minutes
80 to 90minutes
3 to 5 hours 36
MepivacaineHCl 2 percent
withlevonordefrin
1:20,000
Carbocaine (EastmanKodak), Isocaine
(Septodont), Mepivacaine(Henry Schein), Polocaine
(Dentsply), Scandanest(Novocol Pharmaceutical)
40 to 60minutes
60 to 90minutes
3 to 5 hours 36
Prilocaine HCl4 percent
withepinephrine
1:200,000
Citanest Forte (Dentsply) 35 to 45minutes
50 to 70minutes
3 to 6 hours 72
Long Duration BupivacaineHCl 0.5
percent withepinephrine
1:200,000
Bupivacaine (Hospira),Marcaine (Carestream
Health), Vivacaine (NovocolPharmaceutical)
Up to 7 hours Up to 7hours
Up to 12 hours 9
PETERS.qxp:Layout 1 4/19/11 3:51 PM Page 494
JADA 142(5) http://jada.ada.org May 2011 495
April 2000. Articaine is available as a 4 percentsolution, and lidocaine is available as a 2 percentsolution. Both can be combined with various con-centrations of vasoconstrictors. Articaine con-tains a thiophene ring, instead of the benzenering found in lidocaine and other amide localanesthetics; this allows the molecule to diffusemore readily through the nerve membrane owingto increased lipid solubility.5,6 A second moleculardifference is the ester linkage incorporated intothe articaine molecule, which results in hydrol-ysis of articaine by plasma esterases. Ninety to95 percent of articaine is metabolized in theblood by plasma esterases, with the remainderbeing broken down in the liver,5 whereas approxi-mately 90 percent of lidocaine is metabolized bythe liver. The articaine solution’s plasma half-lifehas been reported to be as short as 20 minutes,5versus lidocaine’s half-life of approximately 108minutes in healthy patients.7 Adverse reactionsto articaine are characteristic of those associatedwith other amide-type anesthetics.8 For a healthyadult weighing 70 kilograms, the maximum dosefor a local anesthetic solution equates to sevencarpules (1.7 milliliters) of 4 percent articaine or13 carpules (1.8 mL each) of 2 percent lidocaine.5
Since its introduction at the turn of the cen-tury, this relatively new solution rapidly hasbecome popular with clinicians because of thehope that it may provide increased efficacy. Infact, articaine accounted for approximately 25percent of total sales of dental anesthetics in theUnited States in 2007, second only to lidocaineat 54 percent.9 Although investigators havedesigned various clinical trials to compare arti-caine with a variety of other available anes-thetic solutions, published data do not support aclear superiority of articaine in terms of anes-thetic efficacy. Thus, clinicians still may wonderwhich anesthetic solution will afford them thebest chance of success for a given procedure,particularly in cases of irreversible pulpitis.
Evidence-based medicine is based on assess-ment of the quality of evidence relevant to therisks and benefits of treatments. The Centre forEvidence-Based Medicine in Oxford, England,defined “evidence-based medicine” as “the con-scientious, explicit, and judicious use of currentbest evidence in making decisions about thecare of individual patients.”10 The authors ofsystematic reviews can condense the results ofmany studies into valid and unbiased sum-maries of the best available evidence for a spe-cific clinical problem.11 This type of overviewmay help clinicians stay current while the liter-ature greatly expands. Systematic reviews canprovide an objective summary of the best avail-
able evidence so as to help dentists and theirpatients make informed choices.12 To date, onlyone meta-analysis has been published in whichinvestigators compared the anesthetic successrates of articaine and lidocaine.13 The author ofthis recent review, however, included only dataoriginating from studies that were published inEnglish and involved the use of a specific type ofpain rating scale. In our review, we aim to offera more broad comparison regarding the efficacyof articaine and lidocaine solutions when usedto achieve profound pulpal anesthesia in adults.
METHODSLiterature search. We prepared a protocol andfollowed it throughout the review. In December2009, we identified eligible studies through anelectronic search of MEDLINE and Embasedatabases. We also identified National Libraryof Medicine Medical Subject Heading terms thatwould help us locate the potential studies forreview. The detailed search strategies for eachdatabase were as follows:dMEDLINE: “(((exp Anesthesia, Dental/ (9655)”OR “(exp Anesthesia/ AND (exp Dentistry/ ORexp Stomatognathic system/ OR exp Stomatog-nathic diseases/)))” AND “(exp Carticaine/” OR “septocaine.mp.” OR “ultracaine.mp.” OR“articaine.mp.” OR “carticaine.mp.” OR “Thiophenes/))”dEmbase: “(((‘articaine’/exp OR articaine)” OR “(‘carticaine’/” OR “carticaine)” OR > “(‘ultracaine’/exp” OR “ultracaine)” OR “septocaine” OR “ ‘thiophene > derivative’/de)”AND “(‘dentistry’/exp” OR “(‘mouth’/exp ORmouth)))”
Selection criteria. We selected an articlefor inclusion in the review if it met the followingcriteria: dthe investigators evaluated the pulpal anes-thetic effect of local anesthetic solutions of arti-caine comparatively with lidocaine, using vol-umes of at least 1.0 mL per administration andin combination with a vasoconstrictor;dthe review concerned clinical trials thatinvolved adult human participants;dthe review was published in a peer-reviewedjournal in the period from January 1970through December 2009;dit provided original data generated by meansof a comparative design.
We excluded an article if it did not satisfy theabove criteria, if it did not describe or define themethods for evaluating anesthetic success or ifit did not describe in detail the techniques foradministering the anesthetic solution.
Initially, we reviewed only the titles of the
S T O R YC O V E R
PETERS.qxp:Layout 1 4/19/11 3:51 PM Page 495
20 JADA Middle East vol 2 No 4 Jul-Aug 2011
496 JADA 142(5) http://jada.ada.org May 2011
articles generated by the electronic search, elim-inating a possible source of bias by masking our-selves as to knowledge of the author or thejournal. We first excluded all obviously irrele-vant records (judging only from titles). Next, wereviewed the abstracts of the potential studiesidentified from the title search for appropriate-ness, and we attempted to include as manystudies as possible even if we found the method-ology to be unclear after we reviewed theabstract. At this point, we obtained full-textcopies of all relevant and potentially relevantstudies that appeared to meet the inclusion cri-teria, or for which there were insufficient datain the title and abstract to facilitate a clear deci-sion. We fully assessed these articles.
To locate relevant articles that were not iden-tified by means of the electronic search, we con-ducted a hand search and a table-of-contentssearch. In our hand search, we reviewed the ref-erence lists of all articles that met the inclusioncriteria in an attempt to identify any additionalstudies. In our table-of-contents search, after wereviewed the journal of origin for each study wehad not excluded after abstract review, we tar-geted the journals that accounted for 80 percentof the included studies. We then reviewed thetable of contents for every issue of these jour-nals for the most recent two years of their publi-cation. Additional efforts to supplement thesearch results included searching of books andconference proceedings and the solicitation ofrecommendations from experts in the field.
Data extraction. Using full-text articles, weextracted for analysis detailed information thatincluded, but was not limited to, study type(such as randomized clinical trial, controlledclinical trial, case-control study), populationcharacteristics (for example, participants’ ages),local anesthetic solution and technique investi-gated, means of analyzing anesthetic success(such as electric pulp testing [EPT] or visualanalog scale [VAS] of pain measurement), preop-erative status of specific teeth tested (vital, irre-versibly inflamed or unspecified), missing dataand adverse outcomes. With respect to localanesthetic solutions and techniques investi-gated, we extracted the following details: typeand dose in milligrams of anesthetic used, con-centration of vasoconstrictor, location of admin-istration (arch, specific tooth and aspect[buccal/lingual]) and technique used (infiltrationor nerve block). The outcomes of interest wereanesthetic success or failure, as defined by eachcomparative trial.
Quality assessment. We recorded on thedata abstraction form the methodological
quality of included trials and the indicators ofquality we used. These included proper random-ized allocation of participants to their respectivestudy groups, as well as masking of participantsand evaluators.
We considered a clinical trial “randomized” ifit involved the generation of random sequencesby means of random numbers or tables, a tossedcoin or any other means. If the authors merelyused the term “randomized” or “randomly allo-cated” but did not provide detailed informationregarding the exact method of randomization,we deemed the trial to be “unclear” as regardsto the randomization and sought clarificationfrom the original authors. We considered alloca-tion “concealed” if the article described meas-ures of allocation concealment such as the use ofopaque sealed and sequentially numberedenvelopes, or if anesthetic cartridges were indi-vidually indistinguishable and numberedsequentially. We deemed the examiners of eachtrial to be properly masked if the outcomeassessor could not determine the group to whicha participant had been assigned randomly. Werecorded reporting of adverse events as beingpresent if the authors provided information onsuch events or noted it as “not mentioned” if theauthors did not include a description of anyadverse effects in the results. We considered the“intent to treat” adequate in studies for whichtreatment effects had been observed and evalu-ated on the same day of intervention. For thetrials in which investigators had used acrossover design, we noted whether no lossesoccurred and whether outcome data were avail-able for all randomly assigned participants.Thus, in our “intent to treat” analysis, weincluded all participants in these trials. Weassessed analysis appropriateness and reviewedfunding sources for included trials to evaluateany potential funding bias.
Data analysis. We conducted all statisticalanalysis of the extracted data by using software(Review Manager [RevMan] Version 5.0.25, TheNordic Cochrane Centre, The Cochrane Collabo-ration, Copenhagen, Denmark). We included inthe final analyses only data regarding 4 percentarticaine and 2 percent lidocaine, both with1:100,000 vasoconstrictor. We calculated the Qstatistic value according to the method ofCochran Q test to test for heterogeneity amongthe studies. We estimated treatment differenceand expressed it graphically in a forest plot.
RESULTSSearch results. Our original electronicsearches of MEDLINE and Embase databases
S T O R YC O V E R
PETERS.qxp:Layout 1 4/19/11 3:51 PM Page 496
21JADA Middle East vol 2 No 4 Jul-Aug 2011
496 JADA 142(5) http://jada.ada.org May 2011
articles generated by the electronic search, elim-inating a possible source of bias by masking our-selves as to knowledge of the author or thejournal. We first excluded all obviously irrele-vant records (judging only from titles). Next, wereviewed the abstracts of the potential studiesidentified from the title search for appropriate-ness, and we attempted to include as manystudies as possible even if we found the method-ology to be unclear after we reviewed theabstract. At this point, we obtained full-textcopies of all relevant and potentially relevantstudies that appeared to meet the inclusion cri-teria, or for which there were insufficient datain the title and abstract to facilitate a clear deci-sion. We fully assessed these articles.
To locate relevant articles that were not iden-tified by means of the electronic search, we con-ducted a hand search and a table-of-contentssearch. In our hand search, we reviewed the ref-erence lists of all articles that met the inclusioncriteria in an attempt to identify any additionalstudies. In our table-of-contents search, after wereviewed the journal of origin for each study wehad not excluded after abstract review, we tar-geted the journals that accounted for 80 percentof the included studies. We then reviewed thetable of contents for every issue of these jour-nals for the most recent two years of their publi-cation. Additional efforts to supplement thesearch results included searching of books andconference proceedings and the solicitation ofrecommendations from experts in the field.
Data extraction. Using full-text articles, weextracted for analysis detailed information thatincluded, but was not limited to, study type(such as randomized clinical trial, controlledclinical trial, case-control study), populationcharacteristics (for example, participants’ ages),local anesthetic solution and technique investi-gated, means of analyzing anesthetic success(such as electric pulp testing [EPT] or visualanalog scale [VAS] of pain measurement), preop-erative status of specific teeth tested (vital, irre-versibly inflamed or unspecified), missing dataand adverse outcomes. With respect to localanesthetic solutions and techniques investi-gated, we extracted the following details: typeand dose in milligrams of anesthetic used, con-centration of vasoconstrictor, location of admin-istration (arch, specific tooth and aspect[buccal/lingual]) and technique used (infiltrationor nerve block). The outcomes of interest wereanesthetic success or failure, as defined by eachcomparative trial.
Quality assessment. We recorded on thedata abstraction form the methodological
quality of included trials and the indicators ofquality we used. These included proper random-ized allocation of participants to their respectivestudy groups, as well as masking of participantsand evaluators.
We considered a clinical trial “randomized” ifit involved the generation of random sequencesby means of random numbers or tables, a tossedcoin or any other means. If the authors merelyused the term “randomized” or “randomly allo-cated” but did not provide detailed informationregarding the exact method of randomization,we deemed the trial to be “unclear” as regardsto the randomization and sought clarificationfrom the original authors. We considered alloca-tion “concealed” if the article described meas-ures of allocation concealment such as the use ofopaque sealed and sequentially numberedenvelopes, or if anesthetic cartridges were indi-vidually indistinguishable and numberedsequentially. We deemed the examiners of eachtrial to be properly masked if the outcomeassessor could not determine the group to whicha participant had been assigned randomly. Werecorded reporting of adverse events as beingpresent if the authors provided information onsuch events or noted it as “not mentioned” if theauthors did not include a description of anyadverse effects in the results. We considered the“intent to treat” adequate in studies for whichtreatment effects had been observed and evalu-ated on the same day of intervention. For thetrials in which investigators had used acrossover design, we noted whether no lossesoccurred and whether outcome data were avail-able for all randomly assigned participants.Thus, in our “intent to treat” analysis, weincluded all participants in these trials. Weassessed analysis appropriateness and reviewedfunding sources for included trials to evaluateany potential funding bias.
Data analysis. We conducted all statisticalanalysis of the extracted data by using software(Review Manager [RevMan] Version 5.0.25, TheNordic Cochrane Centre, The Cochrane Collabo-ration, Copenhagen, Denmark). We included inthe final analyses only data regarding 4 percentarticaine and 2 percent lidocaine, both with1:100,000 vasoconstrictor. We calculated the Qstatistic value according to the method ofCochran Q test to test for heterogeneity amongthe studies. We estimated treatment differenceand expressed it graphically in a forest plot.
RESULTSSearch results. Our original electronicsearches of MEDLINE and Embase databases
S T O R YC O V E R
PETERS.qxp:Layout 1 4/19/11 3:51 PM Page 496
JADA 142(5) http://jada.ada.org May 2011 497
identified 165 and 174potentially eligible arti-cles, respectively. Weremoved duplicate records,and after our initialscreening of first titles andthen abstracts, we identi-fied 35 potentially rel-evant clinical trials for fullreview. The various lan-guages of the publicationswere English, German,Croatian and Russian. Wesecured translations ofnon-English articles tofacilitate proper appraisal.We excluded two articlesabout studies involvingpartially or strictly pedi-atric populations.14,15 Onearticle described an inves-tigation of anesthesia inrelation to surgical inter-ventions that did notinclude any form of assess-ment of pulpal anesthesia;therefore, we excluded it.16
We excluded nine articleson the basis of their specific methodologies, suchas absence of randomization, lack of control par-ticipants or nonstandardized assessment ofpulpal anesthesia.17-25 In addition, we excludedarticles in which investigators only assessedinjection pain,26,27 cardiovascular effects or othersystemic effects.28-30 We excluded three trialsbecause the solutions being compared were con-founded by the preadministration of additionalanesthetic before the comparison.31-33 Two trialsdid not meet the minimum volume require-ments as stated in the inclusion criteria.34,35
The remaining 13 studies, all of which weincluded in our review, had been published inseven journals: British Dental Journal; TheJournal of the American Dental Association;Journal of Endodontics; Oral Surgery, Oral Med-icine, Oral Pathology, Oral Radiology, andEndodontology; Quintessence International;Scandanavian Journal of Dental Research; andSchweizerische Monatsschrift für Zahnmedizin.Neither the tables of contents search of thesejournals nor the other search efforts located anyadditional trials that had not already been iden-tified in the previous electronic search. At theend of the search process, then, we considered atotal of 13 articles eligible. Their data form thebasis of this review (Figure 1).
General study characteristics. We catego-
rized each of the 13 included studies1-3,36-45 asrandomized, controlled clinical trials in whichresearchers investigated pulpal anesthesia inadult participants (Table 2).
Study outcomes. Investigators in three ofthe included studies used the VAS to assessanesthetic efficacy, defining success as the par-ticipant’s rating pain as being no greater thanthat considered mild on the pain scale. Ninestudies used electric methods as a measure ofanesthetic success. Researchers in one studyused both techniques in their investigation.
OUTCOMES OF DATA ANALYSESFour of the 13 included studies provided datafrom independent samples. Lacking reporting ofdata in crossover studies necessary to calculatethe dependent odds ratio, we included bothdesigns in the overall analysis and forest plot(Figure 2, page 500).1-3,36-45
We found strong evidence of heterogeneityamong the estimated treatment effects of these13 studies. For all studies combined, the χ2 valueassociated with the test of heterogeneity was23.469 (P = .005). The Cochrane Collaboration46
recommended using a P value < .10, rather thanthe conventional cut-point of P = .05. Addition-ally, if the χ2 value is larger than the df, there isstrong evidence of heterogeneity. For these rea-
S T O R YC O V E R
Potentially relevant articles identified fromMEDLINE (n = 165) and Embase (n = 174)by means of electronic search strategy
(total N = 339)
Additional searching� Reference lists� Table of contents� Handbooks and conference proceedings� Solicitation of expert recommendations (n = 0)
Duplicate records removed(n = 128)
Articles excluded on basis oftitle and abstract
(n = 176)
Full-text articles critically appraised to justifyinclusion of potentially relevant studies
for review (n = 35)
Articles excluded that did notfulfill inclusion criteria
(n = 22)
Articles included in meta-analysis(n = 13)
Figure 1. Flow diagram of the process of manuscript identification and selection. Thirteenstudies were included in the meta-analysis.
PETERS.qxp:Layout 1 4/19/11 3:51 PM Page 497
22 JADA Middle East vol 2 No 4 Jul-Aug 2011
498 JADA 142(5) http://jada.ada.org May 2011
sons, we used a random-effects model of statis-tical analysis, as fixed-effects models are used incases with no evidence of heterogeneity.
Figure 21-3,36-45 presents a forest plot of oddsratios of treatment differences between the two
anesthetic solutions. The combined effect of arti-caine was 2.44 times more likely to produceanesthetic success than was that of lidocaine,and the results were statistically significant (95 percent confidence interval [CI], 1.59-3.76).
S T O R YC O V E R
TABLE 2
Characteristics of included studies.
AUTHOR, YEAR METHODS NO. OF PARTICIPANTS
Srinivasan andColleagues,36 2009
Compared articaine with lidocaine when delivered via buccalinfiltration for maxillary posterior teeth diagnosed with
irreversible pulpitis
40
Tortamano andColleagues,37 2009
Compared articaine with lidocaine during pulpectomy inpatients with irreversible pulpitis in mandibular posterior
teeth, subsequent to IAN† block
40
Evans and Colleagues,38
2008Compared articaine with lidocaine in maxillary infiltrations
of first molars and lateral incisors80
Sherman and Colleagues,39
2008Compared articaine with lidocaine in patients with
irreversible pulpitis in either maxillary or mandibularposterior teeth
40
Robertson andColleagues,1 2007
Compared articaine with lidocaine when given via buccalinfiltration in mandibular posterior teeth, testing from first
premolar to second molar
60
Kanaa and Colleagues,40
2006Compared articaine with lidocaine in mandibular buccal
infiltrations of first molars31
Berlin and Colleagues,41
2005Compared articaine with lidocaine when administered via
computer-controlled intraligamentary injections inmandibular posterior teeth
51
Costa and Colleagues,42
2005Compared articaine with lidocaine for maxillary infiltration
of posterior teeth20
Mikesell and Colleagues,3
2005Compared articaine with lidocaine when administered via
IAN block, testing molars, premolars and incisors57
Claffey and Colleagues,2
2004Compared articaine with lidocaine when administered viaIAN block in patients experiencing irreversible pulpitis in
mandibular posterior teeth
72
Oliviera and Colleagues,43
2004Compared a standard 2.15-milliliter volume of articaine with
the same amount of lidocaine for buccal and lingualinfiltration of maxillary canine teeth
20
Ruprecht and Knoll-Köhler,44 1991
Compared infiltrations of articaine and lidocaine formaxillary central incisors
10
Winther and Nathalang,45
1972Compared the anesthetic efficacy of maxillary infiltrations of1.0-mL articaine for lateral incisors with the same volumes of
lidocaine and mepivacaine
39
* VAS: Visual analog scale.† IAN: Inferior alveolar nerve.‡ EPT: Electric pulp testing.
PETERS.qxp:Layout 1 4/19/11 3:51 PM Page 498
23JADA Middle East vol 2 No 4 Jul-Aug 2011
JADA 142(5) http://jada.ada.org May 2011 499
When we calculated weighted odds ratiosfrom data regarding infiltration anesthesia only(Figure 3),1,36,38-40,42-45 the value increased to 3.81in favor of articaine, indicating an obvious supe-riority of articaine to lidocaine.
Subgroup analysis according toRCT design (that is, RCT withindependent groups versus cross -over design) showed that theoverall finding for infiltrationanesthesia did not change owingto the study design (data notshown). Articaine was shown to beclearly superior.
To enable comparison of theoutcomes of the four mandibularblock studies, we included in theanalysis only data for premolarsand molars from these studies.When we isolated data regardingmandibular block analysis (Figure4A, page 501),2,3,37,39 the weightedodds ratio decreased to 1.57, andarticaine showed a statisticallysignificant better performance (95 percent CI, 1.12-2.21).
When we included only theresults of independent-samplestudies in the mandibular blockanalysis (Figure 4B, page 501),2,37,39
the odds ratio was 1.61 (95 percentCI, 0.74-3.53) and thus we deter-mined that the results no longerwere significantly different.
DISCUSSIONIn this systematic review, weexamined the literature regardingthe use of the local anestheticsolutions articaine and lidocaine,with the goal of evaluating differ-ences in providing anesthetic suc-cess. We targeted and identifiedwell-designed clinical trials inwhich investigators comparedthese two solutions directly. Thir-teen studies fulfilled the inclusioncriteria, and data from them thatrelated to 4 percent articaine and2 percent lidocaine both with1:100,000 vasoconstrictor servedas the basis for a meta-analysis ofthe extracted data. Meta-analysisis the statistical pooling of dataacross studies to generate pooledestimates of effects.47 Benefits ofmeta-analysis include the ability
to improve the power of small studies to answerquestions, and meta-analysis also can helpdetect biases and deficiencies in the design,analysis and interpretation of research.48 Thesemethods can highlight needed improvements in
S T O R YC O V E R
TABLE 2 (CONTINUED)
EVALUATIONSCALE USED
CONCLUSIONS
VAS* Articaine’s success rates were 100 percent for both the firstmolar and the first premolar, and lidocaine’s success rates
were 30 percent in the first premolar and 80 percent in thefirst molar; there was a highly statistically significant
difference
EPT,‡ VAS For patients reporting no pain or mild pain duringpulpectomy, the success rate of articaine
(65 percent) was higher than that of lidocaine (45 percent);however, differences were not statistically significant
EPT In maxillary lateral incisors, articaine exhibited a statisticallysignificantly higher success rate
(88 percent) when compared with lidocaine (62 percent);differences were not significant for first molars (78 percent
versus 73 percent)
VAS Overall anesthetic success was 87.5 percent in both arches;articaine was as effective as, but not statistically superior to,
lidocaine
EPT Lidocaine resulted in anesthetic success ranging from 45 to67 percent, whereas articaine resulted in a success rateranging from 75 to 92 percent; articaine did result in a
statistically significant higher success rate for mandibularbuccal infiltrations
EPT Success rates were 65 percent for articaine and 39 percentfor lidocaine, resulting in a statistically significantly greater
chance for anesthetic success with articaine
EPT Success rates were 74 percent for lidocaine and 86 percentfor articaine solutions; there was no statistical difference
between the two solutions
EPT There were no statistical differences between articaine andlidocaine in terms of anesthetic success
EPT Lidocaine resulted in anesthetic success ranging from 2 to48 percent, whereas articaine resulted in a range of 4 to 54
percent; there was no statistical difference between thearticaine and lidocaine solutions
VAS The success rates of lidocaine (23 percent) and articaine (24percent) revealed no statistical difference; neither solutionresulted in an acceptable rate of success for patients with
irreversible pulpitis
EPT All administrations resulted in pulpal anesthetic success;onset and duration of anesthesia were not statistically
different between the two groups
EPT No statistically significant differences were observed interms of anesthetic success, although articaine offered a
longer duration of anesthesia
EPT Articaine compared well with the other solutions, with the2 percent solution providing a frequency of anesthesia close
to 100 percent
PETERS.qxp:Layout 1 4/19/11 3:51 PM Page 499
24 JADA Middle East vol 2 No 4 Jul-Aug 2011500 JADA 142(5) http://jada.ada.org May 2011
the quality of the data to achieve optimal evidence-based clinical practice. In this way,meta-analysis can be a useful tool in planning anew clinical trial in clinical situations for whichthe evidence is sparse.
The results of this meta-analysis showed thatin a clinical situation, articaine was more likelyto produce anesthetic success than was lido-caine. This higher overall odds ratio of achievinganesthetic success with articaine indicates thatthere is an advantage to using this local anes-thetic. This investigation provided a high level ofevidence in support of articaine’s having greatersuccess than other anesthetic solutions when
used for pulpal anesthesia in dental applications.These results corroborate the findings of arecent meta-analysis that also favored articaineover lidocaine in terms of anesthetic success.13
This review certainly is not without limita-tions. The quality of the underlying studies, theconsistency of results across studies and theprecision of the pooled data affect the strengthof inference from systematic reviews consider-ably.32 Another limitation is the methodologicalheterogeneity of the trials included in thisreview, including variability of masking pro-cedures, evaluation and definition of anestheticsuccess, sample size, experience of operator and
S T O R YC O V E R
Berlin and Colleagues,41 2005
Claffey and Colleagues,2 2004
Costa and Colleagues,42 2005
Evans and Colleagues,38 2008
Kanaa and Colleagues,40 2006
Mikesell and Colleagues,3 2005
Oliviera and Colleagues,43 2004
Robertson and Colleagues,1 2007
Ruprecht and Knoll-Köhler,44 1991
Sherman and Colleagues,39 2008
Srinivasan and Colleagues,36 2009
Tortamano and Colleagues,37 2009
Winther and Nathalang,45 1972
TOTAL (95% CI)
TOTAL EVENTS
Heterogeneity: τ2 = 0.22; χ2 = 23.469 (P = .005); I2 = 62%.Z test for overall effect: Z = 4.05 (P < .0001).CI: Confidence interval.
125
9
20
66
20
118
20
201
20
19
20
13
30
681
153
37
20
80
31
334
20
237
20
20
20
20
30
1,022
107
8
20
54
12
92
20
136
20
16
11
9
28
533
153
35
20
80
31
334
20
237
20
20
20
20
40
1,030
16.3
9.1
Not applicable
13.2
9.7
19.3
Not applicable
17.8
Not applicable
3.1
2.0
7.5
2.0
100.0
1.92 (1.12-3.28)
1.08 (0.37-3.22)
Not estimable
2.27 (1.08-4.77)
2.88 (1.03-8.07)
1.44 (1.03-2.00)
Not estimable
4.15 (2.68-6.43)
Not estimable
4.75 (0.48-46.91)
33.87 (1.80-636.88)
2.27 (0.64-8.11)
26.75 (1.51-473.03)
2.44 (1.59-3.76)
STUDY OR SUBGROUP, YEAR EventsExperimental Control
ADMINISTRATION
Total Events Total WEIGHT (%)ODDS RATIO
(95% CI)ODDS RATIO
(95% CI)
0.01 0.1 1 10 100Favors experimental Favors control
Figure 2. Forest plot of odds ratios from the 13 trials included in the meta-analysis comparing lidocaine versus articaine in terms ofoverall treatment effects, suggesting that articaine has a 2.44 times greater likelihood of anesthetic success than does lidocaine.
STUDY OR SUBGROUP, YEAR EventsExperimental Control
ADMINISTRATION
Total Events Total WEIGHT (%)ODDS RATIO
(95% CI)ODDS RATIO
(95% CI)
Costa and Colleagues,42 2005
Evans and Colleagues,38 2008
Kanaa and Colleagues,40 2006
Oliviera and Colleagues,43 2004
Robertson and Colleagues,1 2007
Ruprecht and Knoll-Köhler,44 1991
Sherman and Colleagues,39 2008
Srinivasan and Colleagues,36 2009
Winther and Nathalang,45 1972
TOTAL (95% CI)
TOTAL EVENTS
20
66
20
20
201
20
10
20
27
404
20
80
31
20
237
20
10
20
28
466
20
54
12
20
136
20
8
11
23
304
20
80
31
20
237
20
9
20
30
467
Not applicable
26.4
11.9
Not applicable
57.6
Not applicable
1.1
0.8
2.2
100.0
Not estimable
2.27 (1.08-4.77)
2.88 (1.03-8.07)
Not estimable
4.15 (2.68-6.43)
Not estimable
3.71 (0.13-103.11)
33.87 (1.80-636.88)
8.22 (0.94-71.82)
3.81 (2.71-5.36)
0.01 0.1 1 10 100Favors experimental Favors control
Heterogeneity: χ2 = 4.915 (P = .43); I2 = 0%.Z test for overall effect: Z = 7.71 (P < .00001).CI: Confidence interval.
Figure 3. Forest plot of odds ratios of lidocaine versus articaine from infiltration studies only, showing articaine to have a treatmenteffect 3.81 times greater than that of lidocaine.
PETERS.qxp:Layout 1 4/19/11 3:51 PM Page 500
25JADA Middle East vol 2 No 4 Jul-Aug 2011 JADA 142(5) http://jada.ada.org May 2011 501
preoperative pulpal status. Clinical practi-tioners should recognize these inherent limita-tions, understand the results and apply themjudiciously to patient care.
One major challenge posed by this meta-analysis was the difference in the methods usedby the investigators in the included trials interms of assessing the success of pulpal anes-thesia. Achieving the soft-tissue signs of localanesthesia is a poor predictor for the presence of profound pulpal anesthesia.49 Thus, our inves-tigation focused on trials in which researchersevaluated the presence or absence of pulpalanesthesia by using electric testing or VAS.Researchers have used EPT to correlate a max-imum reading of 80 on the device to indicateprofound pulpal anesthesia.50,51 Additionally,research has demonstrated that EPT readingsof lower than 80 were associated with painduring operative procedures in asymptomaticteeth.51 Most investigators interested in deter-mining pulpal anesthesia use the EPT method.In this method, anesthetic success often isdefined as the percentage of participants whoachieve two consecutive EPT readings of 80
within 15 minutes of anesthetic administrationand sustain this lack of responsiveness continu-ously for 60 minutes. These criteria help removesome of the subjectivity in assessing pulpalanesthesia, although the evaluation still relieson a patient’s response. The behavior of thepatient and the responses seen in control teethalso require the clinician’s careful attention.52
Using electric testing as a more objective meansof determining pulpal anesthesia has beenuseful in improving the clarity of research out-comes in the area of local anesthesia in den-tistry. The investigators in 10 of the 13 studiesincluded in this review used an electric device todetermine anesthetic success, and those in theother three used solely the VAS (Table 2).
Evaluation of the efficacy of local anestheticsin dentistry is more difficult in symptomaticteeth. One of the most difficult situations thatdentists face routinely is effectively anes-thetizing a tooth that contains an acutelyinflamed vital pulp. In such instances, successrates for traditional anesthetic methods maydrop to unacceptable levels.53 Compounding theproblem is the lack of reliability in determining
S T O R YC O V E R
STUDY OR SUBGROUP, YEAR EventsExperimental Control
ADMINISTRATION
Total Events Total WEIGHT (%)ODDS RATIO
(95% CI)ODDS RATIO
(95% CI)
Claffey and Colleagues,2 2004
Mikesell and Colleagues,3 2005
Sherman and Colleagues,39 2008
Tortamano and Colleagues,37 2009
TOTAL (95% CI)
TOTAL EVENTS
9
107
9
13
138
37
220
10
20
287
8
83
8
9
108
35
220
11
20
286
9.8
81.0
1.9
7.2
100.0
1.08 (0.37-3.22)
1.56 (1.07-2.28}
3.38 (0.29-39.32)
2.27 (0.64-8.11)
1.57 (1.12-2.21)
0.01 0.1 1 10 100Favors experimental Favors control
0.01 0.1 1 10 100Favors experimental Favors control
Heterogeneity: τ2 = 0.00; χ2 = 1.143 (P = .77); I2 = 0%.Z test for overall effect: Z = 2.59 (P < .009).CI: Confidence interval.
STUDY OR SUBGROUP, YEAR EventsExperimental Control
ADMINISTRATION
Total Events Total WEIGHT (%)ODDS RATIO
(95% CI)ODDS RATIO
(95% CI)
Claffey and Colleagues,2 2004
Sherman and Colleagues,39 2008
Tortamano and Colleagues,37 2009
TOTAL (95% CI)
TOTAL EVENTS
9
9
13
31
37
10
20
67
8
8
9
25
35
11
20
66
51.8
10.2
38.0
100.0
1.08 (0.37-3.22)
3.38 (0.29-39.32)
2.27 (0.64-8.11)
1.61 (0.74-3.53)
Heterogeneity: τ2 = 0.00; χ2 = 1.132 (P = .57); I2 = 0%.Z test for overall effect: Z = 1.19 (P = .23).CI: Confidence interval.
A
B
Figure 4. Forest plots of articaine versus lidocaine: mandibular block treatment effects (posterior teeth only). A. Analysis includingboth crossover and independent-sample studies (four trials), indicating a slight advantage of articaine (1.57 times) over lidocaine. B. Analysis of independent-sample studies only (inflamed teeth) indicated that there was no difference in treatment effect between the anesthetic solutions used.
PETERS.qxp:Layout 1 4/19/11 3:51 PM Page 501
26 JADA Middle East vol 2 No 4 Jul-Aug 2011502 JADA 142(5) http://jada.ada.org May 2011
pulpal anesthesia by means of electric testing.Even a lack of response to EPT may not guar-antee that a tooth is experiencing profoundpulpal anesthesia.50,54 Several explanations forthe failure of anesthetic solutions in patientswith such teeth appear in the literature. Nervesarising from inflamed tissues have alteredresting potentials and decreased excitabilitythresholds.55 It also is known that certainclasses of sodium channels are resistant to the action of local anesthetics. A class oftetrodotoxin-resistant sodium channels havebeen shown to be resistant to the measures oflocal anesthetics.56 These channels have beendemonstrated to be upregulated during theinflammatory process and are thought to con-tribute to instances of orofacial hyperalgesia.57
Additionally, pulps that have been diagnosedwith irreversible pulpitis may have an increasedexpression of sodium channels.58 These findingshelp explain why dental patients who seektreatment of pain arising from pulpal pathosismay have difficulty experiencing profoundpulpal anesthesia.
The authors of four of the included studies (twostudies that involved infiltration36,39 and threethat involved mandibular block2,37,39) investigatedlocal anesthetic success in patients who requireddental treatment in teeth that had a preoperativediagnosis of irreversible pulpitis. Because of theaforementioned difficulty in using EPT in suchteeth, the investigators in these four studies usedthe VAS to define the outcome after local anes-thetic administration. This psychometricresponse scale has been used as a measurementinstrument for subjective characteristics such asdental pain, and it has been used successfully indentistry primarily for patients who are sympto-matic preoperatively.2,36,37,39 Although the numberof studies and each study’s sample size weresmall, the data for symptomatic teeth showedthat both infiltration and block administrationhad a treatment effect in favor of articaine, whichin cases involving the use of mandibular blockwas not significant (Figure 4B).
One likely reason that the use of articainehas grown among dentists in the United Statesis the hope that it may become the agent ofchoice for the inferior alveolar nerve (IAN)block. Corbett and colleagues25 reported that the efficacy of 4 percent articaine infiltration(1:100,000 epinephrine) compared with that of 2 percent lidocaine IAN block (1:80,000 epineph-rine) was not significantly different for anes-thetic success in mandibular first molars. Addi-tionally, Jung and colleagues59 found that thesuccess rate of a standard volume of articaine
was not different when used in either buccalinfiltration or IAN block. However, successfulanesthesia after buccal infiltration in mandib-ular posterior teeth appears to be not as likelywhen a lidocaine solution is used. Indeed,researchers in two clinical investigations havestated that articaine resulted in a significantlyhigher success rate for mandibular buccal infil-tration when compared with lidocaine.1,40 All ofthe studies cited in this paragraph wereaccounted for in our systematic review and con-tributed to the final outcome of our review.
Several authors have raised concern that theadministration of articaine solutions could beassociated with an increased risk of incitingadverse events such as paresthesia.8,60-62 Evalu-ating such associations is outside the scope ofthis review. However, among the 1,022 inde-pendent administrations of articaine, the variousauthors reported no presence of short-term orlong-term paresthesia. Reporting of adverseevents among the included trials was not stan-dardized, with several of the authors making nomention of the presence or absence of complica-tions associated with the administration of arti-caine or lidocaine. Investigators in future trialsshould report clearly the presence of adverseevents or state explicitly if none occurred.
CONCLUSIONSWhen comparing the newer articaine solutionwith the gold standard of lidocaine, we identi-fied an emerging trend in our review of pub-lished research. The results of these studiesoften have demonstrated that articaine has asuperior anesthetic efficacy, even though properstatistical scrutiny frequently revealed thatsuch differences were not always statisticallysignificant. The findings of our meta-analysissummarize the unbiased direct comparison ofarticaine and lidocaine and support the argu-ment that articaine does provide a higher rateof anesthetic success. This evidence-basedreview is aimed to aid clinicians in makinginformed, judicious decisions when selecting alocal anesthetic solution.
In this meta-analysis of the data from 13selected clinical trials, we found that the admin-istration of an articaine solution for local anes-thesia in dentistry has an advantage over lido-caine in respect to achieving pulpal anestheticsuccess. When we further stratified injectiontypes, we found that the evidence more stronglysupported articaine’s superiority to lidocainewith infiltration anesthesia; we found weak evi-dence for such differences in mandibular blockanesthesia. When we took into account various
S T O R YC O V E R
PETERS.qxp:Layout 1 4/19/11 3:51 PM Page 502
27JADA Middle East vol 2 No 4 Jul-Aug 2011502 JADA 142(5) http://jada.ada.org May 2011
pulpal anesthesia by means of electric testing.Even a lack of response to EPT may not guar-antee that a tooth is experiencing profoundpulpal anesthesia.50,54 Several explanations forthe failure of anesthetic solutions in patientswith such teeth appear in the literature. Nervesarising from inflamed tissues have alteredresting potentials and decreased excitabilitythresholds.55 It also is known that certainclasses of sodium channels are resistant to the action of local anesthetics. A class oftetrodotoxin-resistant sodium channels havebeen shown to be resistant to the measures oflocal anesthetics.56 These channels have beendemonstrated to be upregulated during theinflammatory process and are thought to con-tribute to instances of orofacial hyperalgesia.57
Additionally, pulps that have been diagnosedwith irreversible pulpitis may have an increasedexpression of sodium channels.58 These findingshelp explain why dental patients who seektreatment of pain arising from pulpal pathosismay have difficulty experiencing profoundpulpal anesthesia.
The authors of four of the included studies (twostudies that involved infiltration36,39 and threethat involved mandibular block2,37,39) investigatedlocal anesthetic success in patients who requireddental treatment in teeth that had a preoperativediagnosis of irreversible pulpitis. Because of theaforementioned difficulty in using EPT in suchteeth, the investigators in these four studies usedthe VAS to define the outcome after local anes-thetic administration. This psychometricresponse scale has been used as a measurementinstrument for subjective characteristics such asdental pain, and it has been used successfully indentistry primarily for patients who are sympto-matic preoperatively.2,36,37,39 Although the numberof studies and each study’s sample size weresmall, the data for symptomatic teeth showedthat both infiltration and block administrationhad a treatment effect in favor of articaine, whichin cases involving the use of mandibular blockwas not significant (Figure 4B).
One likely reason that the use of articainehas grown among dentists in the United Statesis the hope that it may become the agent ofchoice for the inferior alveolar nerve (IAN)block. Corbett and colleagues25 reported that the efficacy of 4 percent articaine infiltration(1:100,000 epinephrine) compared with that of 2 percent lidocaine IAN block (1:80,000 epineph-rine) was not significantly different for anes-thetic success in mandibular first molars. Addi-tionally, Jung and colleagues59 found that thesuccess rate of a standard volume of articaine
was not different when used in either buccalinfiltration or IAN block. However, successfulanesthesia after buccal infiltration in mandib-ular posterior teeth appears to be not as likelywhen a lidocaine solution is used. Indeed,researchers in two clinical investigations havestated that articaine resulted in a significantlyhigher success rate for mandibular buccal infil-tration when compared with lidocaine.1,40 All ofthe studies cited in this paragraph wereaccounted for in our systematic review and con-tributed to the final outcome of our review.
Several authors have raised concern that theadministration of articaine solutions could beassociated with an increased risk of incitingadverse events such as paresthesia.8,60-62 Evalu-ating such associations is outside the scope ofthis review. However, among the 1,022 inde-pendent administrations of articaine, the variousauthors reported no presence of short-term orlong-term paresthesia. Reporting of adverseevents among the included trials was not stan-dardized, with several of the authors making nomention of the presence or absence of complica-tions associated with the administration of arti-caine or lidocaine. Investigators in future trialsshould report clearly the presence of adverseevents or state explicitly if none occurred.
CONCLUSIONSWhen comparing the newer articaine solutionwith the gold standard of lidocaine, we identi-fied an emerging trend in our review of pub-lished research. The results of these studiesoften have demonstrated that articaine has asuperior anesthetic efficacy, even though properstatistical scrutiny frequently revealed thatsuch differences were not always statisticallysignificant. The findings of our meta-analysissummarize the unbiased direct comparison ofarticaine and lidocaine and support the argu-ment that articaine does provide a higher rateof anesthetic success. This evidence-basedreview is aimed to aid clinicians in makinginformed, judicious decisions when selecting alocal anesthetic solution.
In this meta-analysis of the data from 13selected clinical trials, we found that the admin-istration of an articaine solution for local anes-thesia in dentistry has an advantage over lido-caine in respect to achieving pulpal anestheticsuccess. When we further stratified injectiontypes, we found that the evidence more stronglysupported articaine’s superiority to lidocainewith infiltration anesthesia; we found weak evi-dence for such differences in mandibular blockanesthesia. When we took into account various
S T O R YC O V E R
PETERS.qxp:Layout 1 4/19/11 3:51 PM Page 502
JADA 142(5) http://jada.ada.org May 2011 503
RCT designs, we found the difference in successrates between articaine and lidocaine to be sta-tistically significant when the method of admin-istration was infiltration or mandibular block inhealthy teeth, but we found no statistically sig-nificant difference between the two when amandibular nerve block was used in sympto-matic teeth.
Implications for research. Well-designedand properly executed RCTs provide the bestevidence regarding the efficacy of health careinterventions, whereas trials with inadequatemethodological approaches may be associatedwith overestimation of treatment effects. Addi-tional well-designed and fully reported compar-ative effectiveness trials investigating the dif-ference in anesthetic success between articaineand lidocaine may further strengthen the evi-dence that formed the basis for this review.
Implications for practice. Clinicians mayexpect a solution of 4 percent articaine (with1:100,000 epinephrine) to provide a greaterprobability of anesthetic success than a solutionof 2 percent lidocaine (with 1:100,000 epineph-rine). The superiority of articaine is most signif-icant when used during local infiltration anes-thesia. Regarding the relative strength oftreatment effects among multiple quantitativestudies, we can state that within a 95 percentCI, the true odds ratio of articaine (2.44) indi-cates that this anesthetic is 1.59 to 3.76 timesmore likely to produce anesthetic success thanis lidocaine. When we considered infiltrationdata only, we found that the results of our meta-analysis indicated that articaine is an estimated3.81 times more likely to produce anestheticsuccess than is a similar volume of lidocaine.There is weak evidence that the use of articaineallows for a higher percentage of anesthetic suc-cess when administered via a mandibular block,and thus it is premature to recommend arti-caine as a substitute for lidocaine in achieving asuccessful mandibular block. �
Disclosure. None of the authors reported any disclosures.
1. Robertson D, Nusstein J, Reader A, Beck M, McCartney M. Theanesthetic efficacy of articaine in buccal infiltration of mandibularposterior teeth. JADA 2007;138(8):1104-1112.
2. Claffey E, Reader A, Nusstein J, Beck M, Weaver J. Anestheticefficacy of articaine for inferior alveolar nerve blocks in patients withirreversible pulpitis. J Endod 2004;30(8):568-571.
3. Mikesell P, Nusstein J, Reader A, Beck M, Weaver J. A com-parison of articaine and lidocaine for inferior alveolar nerve blocks. J Endod 2005;31(4):265-270.
4. Donaldson D, James-Perdok L, Craig BJ, Derkson GD,Richardson AS. A comparison of Ultracaine DS (articaine HCl) andCitanest forte (prilocaine HCl) in maxillary infiltration and mandib-ular nerve block. J Can Dent Assoc 1987;53(1):38-42.
5. Oertel R, Rahn R, Kirch W. Clinical pharmacokinetics of articaine.Clin Pharmacokinet 1997;33(6):417-425.
6. Vree TB, Baars AM, van Oss GE, Booij LH. High-performance
liquid chromatography and preliminary pharmacokinetics of arti-caine and its 2-carboxy metabolite in human serum and urine. J Chromatogr 1988;424(2):440-444.
7. Thomson PD, Melmon KL, Richardson JA, et al. Lidocaine phar-macokinetics in advanced heart failure, liver disease, and renalfailure in humans. Ann Intern Med 1973;78(4):499–508.
8. Malamed SF, Gagnon S, Leblanc D. Articaine hydrochloride: astudy of the safety of a new amide local anesthetic. JADA 2001;132(2):177-185.
9. Pogrel MA. Permanent nerve damage from inferior alveolarnerve blocks: an update to include articaine. J Calif Dent Assoc 2007;35(4):271-273.
10. Sackett DL, Rosenberg WM, Gray JA, Haynes RB, RichardsonWS. Evidence based medicine: what it is and what it isn’t. BMJ 1996;312(7023):71-72.
11. Carr AB. Systematic reviews of the literature: the overview andmeta-analysis. Dent Clin North Am 2002;46(1):79-86.
12. Needleman IG. A guide to systematic reviews. J Clin Periodontol2002;29(suppl 3):6-9.
13. Katyal V. The efficacy and safety of articaine versus lignocainein dental treatments: a meta-analysis (published online ahead ofprint Dec. 16, 2009). J Dent 2010;38(4):307-317. doi:10.1016/j.jdent.2009.12.003.
14. Ram D, Peretz B. Administering local anaesthesia to paediatricdental patients: current status and prospects for the future. Int JPaediatr Dent 2002;12(2):80-89.
15. Malamed SF, Gagnon S, Leblanc D. A comparison between arti-caine HCl and lidocaine HCl in pediatric dental patients. PediatrDent 2000;22(4):307-311.
16. Sierra Rebolledo A, Delgado Molina E, Berini Aytís L, GayEscoda C. Comparative study of the anesthetic efficacy of 4 percentarticaine versus 2 percent lidocaine in inferior alveolar nerve blockduring surgical extraction of impacted lower third molars. Med OralPatol Oral Cir Bucal 2007;12(2):e139-e144.
17. Maniglia-Ferreira C, Almeida-Gomes F, Carvalho-Sousa B, etal. Clinical evaluation of the use of three anesthetics in endodontics.Acta Odontol Latinoam 2009;22(1):21-26.
18. Matthews R, Drum M, Reader A, Nusstein J, Beck M. Articainefor supplemental buccal mandibular infiltration anesthesia inpatients with irreversible pulpitis when the inferior alveolar nerveblock fails. J Endod 2009;35(3):343-346.
19. Anisimova EN, Zorian EV, Shuga lov IA. The characteristics ofthe action of Carpule-delivered local anesthetics and their combina-tions with vasoconstrictors (a preliminary report) (in Russian). Stom-atologiia (Mosk) 1997;76(6):25-29.
20. Amsel V, Katanec D. Comparison of the effect the local anes-thetics xylocaine and cystocaine in oral medicine (in Croatian). ActaStomatol Croat 1986;20(3):199-206.
21. Sitzmann F, Lindorf HH. Comparative experimental measure-ment of the stimulus threshold of the effect of the local anestheticUltracaine (Carticaine) (in German). Dtsch Zahnarztl Z 1976;31(2):128-130.
22. Khoury F, Hinterthan A, Schürmann J, Arns H. Clinical com-parative study of local anesthetics: random double-blind study withfour commercial preparations (in German). Dtsch Zahnarztl Z 1991;46(12):822-824.
23. Szabó G, Gáspár L, Divinyi T. Recent clinical experiences with Ultracaine preparations versus different lidocaines (in German).Z Stomatol 1988;85(4):235-238.
24. Mehta Fali S, Daftary Dinesh K, Billimoria RB, Irani RR. Carticaine in dentistry. J Indian Dent Assoc 1983;55(12):501-505.
25. Corbett IP, Kanaa MD, Whitworth JM, Meechan JG. Articaineinfiltration for anesthesia of mandibular first molars. J Endod 2008;34(5):514-518.
26. Wahl MJ, Schmitt MM, Overton DA. Injection pain of prilocaineplain, mepivacaine plain, articaine with epinephrine, and lidocainewith epinephrine. Gen Dent 2006;54(3):168-171.
27. Nusstein J, Burns Y, Reader A, Beck M, Weaver J. Injection painand postinjection pain of the palatal-anterior superior alveolar injec-tion, administered with the Wand Plus system, comparing 2 percentlidocaine with 1:100,000 epinephrine to 3 percent mepivacaine. OralSurg Oral Med Oral Pathol Oral Radiol Endod 2004;97(2):164-172.
28. Elad S, Admon D, Kedmi M, et al. The cardiovascular effect oflocal anesthesia with articaine plus 1:200,000 adrenalin versus lido-caine plus 1:100,000 adrenalin in medically compromised cardiacpatients: a prospective, randomized, double blinded study. Oral SurgOral Med Oral Pathol Oral Radiol Endod 2008;105(6):725-730.
29. Oertel R, Oertel A, Weile K, Gramatté T, Feller K. The concen-
S T O R YC O V E R
PETERS.qxp:Layout 1 4/19/11 3:51 PM Page 503
28 JADA Middle East vol 2 No 4 Jul-Aug 2011
504 JADA 142(5) http://jada.ada.org May 2011
tration of local anesthetics in the dental alveolus: comparativestudies of lidocaine and articaine in the mandible and maxilla (inGerman). Schweiz Monatsschr Zahnmed 1994;104(8):952-955.
30. Sack U, Kleemann PP. Intraoral conduction anesthesia withepinephrine-containing local anesthetics and arterial epinephrineplasma concentration. Anesth Pain Control Dent 1992;1(2):77-80.
31. Aggarwal V, Jain A, Kabi D. Anesthetic efficacy of supplementalbuccal and lingual infiltrations of articaine and lidocaine after aninferior alveolar nerve block in patients with irreversible pulpitis. J Endod 2009;35(7):925-929.
32. Haase A, Reader A, Nusstein J, Beck M, Drum M. Comparinganesthetic efficacy of articaine versus lidocaine as a supplementalbuccal infiltration of the mandibular first molar after an inferioralveolar nerve block (published correction appears in JADA 2008;139[10]:1312). JADA 2008;139(9):1228-1235.
33. Rosenberg PA, Amin KG, Zibari Y, Lin LM. Comparison of 4percent articaine with 1:100,000 epinephrine and 2 percent lidocainewith 1:100,000 epinephrine when used as a supplemental anesthetic.J Endod 2007;33(4):403-405.
34. Abdulwahab M, Boynes S, Moore P, et al. The efficacy of sixlocal anesthetic formulations used for posterior mandibular buccalinfiltration anesthesia. JADA 2009;140(8):1018-1024.
35. Vähätalo K, Antila H, Lehtinen R. Articaine and lidocaine formaxillary infiltration anesthesia. Anesth Prog 1993;40(4):114-116.
36. Srinivasan N, Kavitha M, Loganathan CS, Padmini G. Com-parison of anesthetic efficacy of 4 percent articaine and 2 percentlidocaine for maxillary buccal infiltration in patients with irre-versible pulpitis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod2009;107(1):133-136.
37. Tortamano IP, Siviero M, Costa CG, Buscariolo IA, Armonia PL.A comparison of the anesthetic efficacy of articaine and lidocaine inpatients with irreversible pulpitis (published online ahead of printDec. 12, 2008). J Endod 2009;35(2):165-168.
38. Evans G, Nusstein J, Drum M, Reader A, Beck M. A prospec-tive, randomized, double-blind comparison of articaine and lidocainefor maxillary infiltrations (published online ahead of print Feb. 7,2008). J Endod 2008;34(4):389-393. doi:10.1016/j.joen.2008.01.004.
39. Sherman MG, Flax M, Namerow K, Murray PE. Anesthetic effi-cacy of the Gow-Gates injection and maxillary infiltration with arti-caine and lidocaine for irreversible pulpitis (published online aheadof print April 25, 2008). J Endod 2008;34(6):656-659. doi:10.1016/j.joen.2008.02.016.
40. Kanaa MD, Whitworth JM, Corbett IP, Meechan JG. Articaineand lidocaine mandibular buccal infiltration anesthesia: a prospectiverandomized double-blind cross-over study (published online ahead ofprint Feb. 17, 2006). J Endod 2006;32(4):296-298. doi:10.1016/j.joen.2005.09.016.
41. Berlin J, Nusstein J, Reader A, Beck M, Weaver J. Efficacy ofarticaine and lidocaine in a primary intraligamentary injectionadministered with a computer-controlled local anesthetic deliverysystem. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2005;99(3):361-366.
42. Costa CG, Tortamano IP, Rocha RG, Francischone CE, Torta-mano N. Onset and duration periods of articaine and lidocaine onmaxillary infiltration. Quintessence Int 2005;36(3):197-201.
43. Oliveira PC, Volpato MC, Ramacciato JC, Ranali J. Articaineand lignocaine efficiency in infiltration anaesthesia: a pilot study. BrDent J 2004;197(1):45-46.
44. Ruprecht S, Knoll-Köhler E. A comparative study of equimolarsolutions of lidocaine and articaine for anesthesia: a randomized
double-blind cross-over study (in German). Schweiz Monatsschr Zahnmed 1991;101(10):1286-1290.
45. Winther JE, Nathalang B. Effectivity of a new local analgesicHoe 40 045. Scand J Dent Res 1972;80(4):272-278.
46. Higgins JP, Green S, eds. Cochrane Handbook for SystematicReviews of Interventions. Version 5.0.2 (updated September 2009).Oxford, England: The Cochrane Collaboration; 2009. “www.cochrane-handbook.org/”. Accessed March 13, 2011.
47. Manchikanti L. Evidence-based medicine, systematic reviews,and guidelines in interventional pain management, part I: introduc-tion and general considerations. Pain Physician 2008;11(2):161-186.
48. Ioannidis JP. Interpretation of tests of heterogeneity and biasin meta-analysis. J Eval Clin Pract 2008;14(5):951-957.
49. Hannan L, Reader A, Nist R, Beck M, Meyers WJ. The use ofultrasound for guiding needle placement for inferior alveolar nerveblocks. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1999;87(6):658-665.
50. Dreven LJ, Reader A, Beck M, Meyers WJ, Weaver J. An evalu-ation of an electric pulp tester as a measure of analgesia in humanvital teeth. J Endod 1987;13(5):233-238.
51. Certosimo AJ, Archer RD. A clinical evaluation of the electricpulp tester as an indicator of local anesthesia. Oper Dent 1996;21(1):25-30.
52. Lin J, Chandler NP. Electric pulp testing: a review (publishedonline ahead of print Feb. 20, 2008). Int Endod J 2008;41(5):365-374.doi:10.1111/j.1365-2591.2008.01375.x.
53. Nusstein J, Reader A, Nist R, Beck M, Meyers WJ. Anestheticefficacy of the supplemental intraosseous injection of 2 percent lido-caine with 1:100,000 epinephrine in irreversible pulpitis. J Endod1998;24(7):487-491.
54. Hsiao-Wu GW, Susarla SM, White RR. Use of the cold test as ameasure of pulpal anesthesia during endodontic therapy: a random-ized, blinded, placebo-controlled clinical trial (published online aheadof print Feb. 23, 2007). J Endod 2007;33(4):406-410. doi:10.1016./j.joen.2006.12.009.
55. Byers MR, Taylor PE, Khayat BG, Kimberly CL. Effects ofinjury and inflammation on pulpal and periapical nerves. J Endod1990;16(2):78-84.
56. Roy ML, Narahashi T. Differential properties of tetrodotoxin-sensitive and tetrodotoxin-resistant sodium channels in rat dorsalroot ganglion neurons. J Neurosci 1992;12(6):2104-2111.
57. Morgan JR, Gebhart GF. Characterization of a model of chronicorofacial hyperalgesia in the rat: contribution of NA (V) 1.8 (pub-lished online ahead of print March 12, 2008). J Pain 2008;9(6):522-531. doi:10.1016/j.jpain.2008.01.326.
58. Malamed SF. Pharmacology of local anesthetics. In: Handbookof Local Anesthesia. 5th ed. St. Louis: Mosby; 2004:24-37.
59. Jung I, Kim J, Kim E, Lee C, Lee SJ. An evaluation of buccalinfiltrations and inferior alveolar nerve blocks in pulpal anesthesiafor mandibular first molars. J Endod 2008;34(1):11-13.
60. Haas DA. Articaine and paresthesia: epidemiological studies. J Am Coll Dent 2006;73(3):5-10.
61. Haas DA, Lennon D. A 21 year retrospective study of reports ofparesthesia following local anesthetic administration. J Can DentAssoc 1995;61(4):319-320, 323-326, 329-330.
62. Garisto GA, Gaffen AS, Lawrence HP, Tenenbaum HC, HaasDA. Occurrence of paresthesia after dental local anesthetic adminis-tration in the United States (published correction appears in JADA2010;141[8]:944). JADA 2010;141(7):836-844.
S T O R YC O V E R
PETERS.qxp:Layout 1 4/19/11 3:51 PM Page 504
Recommended